Fosun Pharmaceutical (02196) plans to buy back no more than HK$1 billion H shares

According to Zhitong Finance App News, Fosun Pharmaceutical (02196) issued an announcement. Based on confidence in the Group's development prospects and recognition of intrinsic value, according to the general authorization granted by the company's shareholders at the company's annual general meeting of shareholders, the H share class shareholders' meeting and the A share class shareholders' meeting held on June 16, 2026, to repurchase H shares, and with the approval of the board of directors, the company plans to repurchase H shares within 12 months from August 27, 2026. The total capital to be repurchased for H shares does not exceed HK$1 billion. The company will determine the purpose of such repurchased H shares based on factors such as H share repurchase authorization and market conditions, including but not limited to cancelling the repurchased H shares or holding them as treasury shares.

The board of directors is confident in the Group's business development and prospects, and believes that the current price of H shares is lower than its actual value. Based on this, the Board believes that implementing the share repurchase plan is in the best interests of the company and its shareholders as a whole.